Cagrilintide

Cagrilintide is a long-acting, acylated amylin analogue that functions as a non-selective agonist of amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR). Developed by Novo Nordisk, it is designed for once-weekly subcutaneous administration with a half-life of approximately 8 days, addressing obesity and type 2 diabetes through appetite suppression, delayed gastric emptying, and glucagon inhibition. Clinical trials have demonstrated remarkable weight loss efficacy, particularly when combined with semaglutide (branded as CagriSema), with the REDEFINE 1 trial showing 60% of participants achieving at least 20% body weight reduction. Cagrilintide represents a significant advancement in obesity pharmacotherapy by leveraging the complementary mechanisms of amylin and GLP-1 receptor agonism.

Weight Loss and Body Composition

Cagrilintide demonstrates dose-dependent, clinically significant weight reduction both as monotherapy and in combination therapy. In the phase 2 dose-finding trial, cagrilintide monotherapy (0.3-4.5 mg weekly) produced 6.0-10.8% body weight loss over 26 weeks compared to 3.0% with placebo^[2]. The combination with semaglutide (CagriSema) yields superior results, with the phase 3 REDEFINE 1 trial showing a mean 20.4% weight reduction versus 3.0% with placebo at week 68, with 60% of participants achieving ≥20% weight loss and 23% achieving ≥30% weight loss^[4][5]. In the REDEFINE 2 trial involving adults with type 2 diabetes, CagriSema produced 13.7% weight loss compared to 3.4% with placebo^[5]. Preclinical studies demonstrate that cagrilintide preferentially reduces fat mass while preserving lean mass, a therapeutically favorable metabolic profile^[9].

Appetite Suppression and Satiety

Cagrilintide exerts powerful anorectic effects through brain amylin receptors, particularly AMY1R and AMY3R, which are essential for its weight-lowering action^[9][11]. The peptide activates both homeostatic and hedonic brain regions controlling appetite, inducing sustained satiety signals that reduce food intake^[1][11]. Unlike shorter-acting amylin analogues requiring multiple daily injections, cagrilintide's long-acting formulation with fatty acid acylation enables once-weekly dosing while maintaining consistent appetite suppression^[1][10]. The combination with semaglutide produces additive effects on appetite reduction through complementary mechanisms: cagrilintide's amylin receptor activation and semaglutide's GLP-1 receptor agonism^[6].

Glycemic Control in Type 2 Diabetes

In adults with type 2 diabetes, CagriSema demonstrates superior glycemic improvements compared to monotherapy. The phase 2 trial showed mean HbA1c reduction of 2.2% with combination therapy versus 1.8% with semaglutide alone and 0.9% with cagrilintide alone at 32 weeks^[3]. In REDEFINE 2, 73.5% of participants achieved HbA1c ≤6.5% with CagriSema compared to 15.9% with placebo^[5]. The combination also improved time-in-range to 88.9% versus 76.2% with semaglutide monotherapy^[3]. Notably, 88% of participants with prediabetes returned to normoglycemia with CagriSema treatment^[4]. These effects occur without increased hypoglycemia risk, with no level 2 or 3 hypoglycemic events reported in clinical trials^[3][5].

Cardiometabolic Benefits

Cagrilintide therapy produces favorable effects on multiple cardiometabolic parameters beyond weight loss. Clinical trials demonstrate significant reductions in waist circumference, systolic blood pressure, and improvements in lipid profiles^[2][3]. The compound delays gastric emptying and suppresses glucagon release from pancreatic alpha cells, contributing to improved glucose homeostasis^[1][11]. Fasting plasma glucose decreased by 3.3 mmol/L with CagriSema versus 1.7 mmol/L with cagrilintide alone in the phase 2 diabetes trial^[3]. A thorough QT study confirmed that cagrilintide does not produce clinically relevant cardiac repolarization prolongation, indicating no increased risk of ventricular arrhythmias.

Pharmacokinetic Advantages

The lipidated structure of cagrilintide provides exceptional pharmacokinetic properties enabling once-weekly administration. The compound exhibits a half-life of 159-195 hours (approximately 8 days) with dose-proportional exposure, time to maximum concentration of 24-72 hours, and stable steady-state levels supporting convenient dosing^[7][10]. When co-administered with semaglutide, no clinically relevant pharmacokinetic drug-drug interactions occur, allowing safe combination therapy^[7].

Gastrointestinal Adverse Events

The most common adverse events with cagrilintide are gastrointestinal in nature, including nausea, constipation, and diarrhea, which are typically mild to moderate, transient, and dose-dependent^[2][3][7]. In the phase 2 weight management trial, 41-63% of participants receiving cagrilintide experienced gastrointestinal events versus 32% with placebo, with nausea affecting 20-47% versus 18% respectively^[2]. In the REDEFINE 1 trial, gastrointestinal adverse events occurred in 79.6% of the CagriSema group versus 39.9% of placebo recipients, though most were transient and mild-to-moderate in severity^[4]. The phase 1b trial confirmed that concomitant cagrilintide and semaglutide administration was well tolerated with manageable gastrointestinal side effects^[7].

Treatment Discontinuation and Serious Events

Permanent treatment discontinuation occurred in approximately 10% of participants in the phase 2 weight management trial, with 4% discontinuing due to adverse events^[2]. Importantly, no fatal adverse events were reported across clinical trials^[3][4][5]. The systematic review and meta-analysis found that cagrilintide demonstrated significantly lower rates of vomiting compared to alternative obesity treatments, potentially offering better tolerability for patients with gastrointestinal sensitivity^[10]. Most adverse events were similar across treatment groups in terms of severity and frequency^[2][7].

Injection Site Reactions

Administration-site reactions have been reported with cagrilintide, though specific incidence rates and severity were not detailed in the primary clinical trials^[2][3]. These reactions are common with subcutaneous peptide therapies and are generally manageable.

Hypoglycemia and Cardiac Safety

Cagrilintide demonstrates excellent safety regarding hypoglycemia and cardiac effects. In trials involving participants with type 2 diabetes, no level 2 or 3 hypoglycemia events were reported, even with combination therapy^[3][5]. A dedicated thorough QT study in 105 healthy participants confirmed that cagrilintide at supratherapeutic doses (4.5 mg) does not cause clinically relevant QTc prolongation, with all confidence interval upper limits remaining below the critical 10-millisecond threshold, indicating no increased risk of ventricular tachyarrhythmias.

Long-term Safety Profile

The phase 3 REDEFINE trials evaluated safety over 68 weeks, demonstrating an acceptable safety profile with manageable adverse events^[4][5]. The combination CagriSema regimen showed similar safety patterns to individual components, with no unexpected adverse events emerging from the drug combination^[3][7]. Review articles conclude that cagrilintide alone and in combination with semaglutide has a favorable safety profile supporting further development for sustained weight management^[6][11].

Contraindications and Monitoring

While specific contraindications are still being established through ongoing clinical trials, patients with known hypersensitivity to cagrilintide or its components should avoid use. Given the gastrointestinal effects, careful dose escalation is recommended to minimize adverse events^[2][7]. The peptide's mechanism through amylin receptors AMY1R and AMY3R in the brain suggests these receptors are essential for therapeutic efficacy, and individuals with conditions affecting these pathways may have altered responses^[9].